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• How to use PSA more effectively 
• Treatment of localized prostate cancer 
• Treatment related adverse effects 
2013 Estimated Cancer Incidence 
*Excluding basal and squamous cell skin cancers 
*Excluding basal and squamous cell skin cancers 
2013 Estimated Cancer Deaths 



AUA Guidelines 
• < 40 years: do not screen 
• 40-54 years: do not routinely screen unless 
high risk (family history or race) 
• 55-69 years: shared decision making 
– Screening interval of ≥ 2 years instead of annual 
• ≥70 years or <10-15 year life expectancy: 
do not routinely screen 
 
 
PLCO 
• ~76,700 men, f/u: 13 yrs 
• No difference in mortality 
• 44% had undergone prior 
screening 
• 52% contamination in 
control arm 
• ~40% compliance with 
biopsy recommendation 
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ERSPC 
• 182,160 men, f/u: 11 yrs 
• 21% mortality reduction 
• 29% after adjustment for 
non-compliance 
• Number needed to be 
invited to screen: 1055 
• Number of cancers that 
need to be detected: 37 
What should you do? 
Do not screen at all 
What should you do? 
Do not screen at all 
or 
Screen, but maximize benefit and 
minimize harm 
How to use PSA more effectively 
• Screen the right patients 
• Re-check PSA in several weeks 
• Risk stratify by checking PSA early 
• Reduce the fear of ‘cancer’ 
• Talk to and partner with your Urologist/s 
 
Screen the right patients 
• Screen patients with life expectancy 
>10-15 years 
• Do not screen elderly patients or those 
with co-morbidities that limit life 
expectancy 
• Older men are 
being 
inappropriately 
screened 
 
 Unpublished data 
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Risk stratify by checking PSA early 
• PSA at an early age predicts the risk of 
having, and the risk of developing 
metastases or mortality 
• 75th centile: 
– Age 45-50: 1.0 ng/ml 
– Age 60:      2.0 ng/ml 
Long term prostate cancer prediction 
• PSA measured at 
age 44-50 predicts 
long term risk of 
prostate cancer 
and of advanced 
cancer 
• 75th centile ~1 
ng/ml 
Lilja JCO 2007; Lilja Nat Rev Ca 2008; 
Lilja Cancer 2011 
90% of deaths occurred in men with PSA > 2ng/ml 
90% of deaths occurred in men with PSA > 2ng/ml 
75th centile: 
Age 45-50: 1.0 ng/ml 
Age 60:      2.0 ng/ml 
Personalized screening schedule 
• If PSA less than population median for age 
then consider not re-screening at all or re-
screen after 5 years 
• If PSA between 50th -75th centile then screen 
q2-4 years 
• If PSA > 75th centile then annual screening 
and consider biopsy at lower thresholds 
 
• PSA distribution in the US population: 
• http://www.cdc.gov/nchs/data/ad/ad379.pdf  
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Reduce the fear of ‘cancer’ 
• Most men with prostate cancer do not 
die from the cancer but die with the 
cancer 
• Some experts suggest that the word 
‘cancer’ for Gleason 6 (low grade) 
prostate cancer should not be used 
• Introduce ‘Active surveillance’ early-on 
Partner with your urologist/s 
• Talk to your urologist about their beliefs 
and practices about PSA screening 
• Partner with them to reduce over-
diagnosis and over-treatment of your 
patients 
• Help them promote active surveillance 
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Treatment of localized prostate 
cancer 
• Active surveillance 
• Surgery 
– Robotic assisted laparoscopic surgery 
– Open prosatectomy 
• Radiation 
– Brachytherapy 
– External beam 
Active Surveillance 
• Excellent option for low risk cancer, for 
elderly patients and those with limited 
life expectancy 
• Involves periodic disease monitoring 
with PSA, DRE, repeat biopsy etc.  
 
• 450 patients 
• 10 yr overall 
survival: 68 % 
• 10 yr cancer 
specific survival: 
97.2% 
Challenges 
• ‘Cancer’ is a scary word 
• Patient anxiety: want to be treated 
• Pressure from family and friends 
 
• Medico-legal concerns 
 
SURGERY 
PIVOT Trial: United States 
SPCG-4 Trial: Scandinavian trial 
SPCG-4 Trial 
• Started in the Pre-PSA era 
• Patient’s had higher risk cancer than in 
the PIVOT trial 
• 695 men, ~23 years follow-up 
• Surgery superior to watchful waiting, 
HR: 0.56 
• Number needed to treat to prevent one 
death: 8 
 

SPCG-4 
• Greater benefit in younger men (<65) 
– HR: 0.45, NNT ~4  
• Greater benefit in intermediate-risk  
cancer 
– HR: 0.38 
PIVOT trial 
• PSA era: so lower risk men 
• 731 men, 10 year median follow-up 
• No benefit of surgery: HR: 0.88 
• But 
– Improved survival with surgery if PSA > 10 
or men have intermediate risk cancer 
 


PIVOT 
PSA era 
Lower risk cancer 
10 year follow-up 
No diff. between 
surgery and Wawa 
But surgery may be 
superior for higher 
risk cancer 
 
SPCG-4 
Pre-PSA era 
Higher risk cancer 
23 year follow-up 
Surgery superior to 
WaWa 
Especially if <65y age 
or intermediate risk 
cancer 
RADIATION 
• Reasonable choice for treatment 
• Never been compared with watchful 
waiting or with surgery in a RCT 
• Traditionally surgery and XRT thought 
to be equal for cancer control 
• Several high quality but retrospective 
studies show that Surgery is superior to 
radiation, especially for higher risk 
cancer 
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TREATMENT RELATED  
ADVERSE EFFECTS 

Risk of secondary malignancies  
after XRT is greater for younger men 
TAKE HOME MESSAGES 
• USPSTF does not recommend PSA 
screening 
– Concern about over-diagnosis and over-
treatment 
• AUA recommends shared decision making 
 
• ERSPC trial showed 21% reduction in 
mortality with PSA screening 
– Number of cancer that need to be detected: 37 
• Several strategies to use PSA more 
effectively and reduce over-diagnosis 
– Do not screen elderly or with limited life 
expectancy 
– Re-check PSA in several weeks 
– Baseline PSA at an early age predicts long 
term risk of cancer metastases and 
mortality 
TAKE HOME MESSAGES 
• Low risk cancer: 
– Active surveillance (reduce overtreatment) 
• Intermediate or High risk cancer 
– Surgery or XRT 
– Surgery may be superior to XRT 
• Both surgery and XRT have long term 
adverse effects 
– Surgery: urinary and sexual effects 
– XRT: also bowel function and risk of 
secondary malignancies 
TAKE HOME MESSAGES 
Questions ? 
